Successful Low-Dose Immune Tolerance Induction Regimen Using Multiple Plasma-Derived Factor VIII Concentrates

被引：0
|
作者：
Colella, M. [1 ]
Montalvao, S. [1 ]
Sambo, A. [1 ]
De Paula, E. [1 ]
Ozelo, M. [1 ]
机构：
[1] Univ Estadual Campinas, Hemophilia Unit Claudio LP Correa INCT Sangue Hem, Campinas, Brazil
来源：
HAEMOPHILIA | 2012年 / 18卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：92 / 92
页数：1
相关论文
共 50 条
  • [31] Inhibitor development and efficacy of recombinant vs. plasma-derived factor VIII concentrates in haemophilia A patients
    Siegmund, B.
    Richter, H.
    Pollmann, H.
    Orlovic, M.
    Gottstein, S. .
    Klamroth, R.
    HAEMOPHILIA, 2008, 14 : 51 - 51
  • [32] Incidence of inhibitors in haemophilia A patients - a review of recent studies of recombinant and plasma-derived factor VIII concentrates
    Scharrer, I
    Bray, GL
    Neutzling, O
    HAEMOPHILIA, 1999, 5 (03) : 145 - 154
  • [33] Timing and severity of inhibitor development in recombinant versus plasma-derived factor VIII concentrates: a SIPPET analysis
    Peyvandi, F.
    Cannavo, A.
    Garagiola, I.
    Palla, R.
    Mannucci, P. M.
    Rosendaal, F. R.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2018, 16 (01) : 39 - 43
  • [34] The safety of plasma-derived von Willebrand/factor VIII concentrates in the management of inherited von Willebrand disease
    Federici, Augusto B.
    EXPERT OPINION ON DRUG SAFETY, 2009, 8 (02) : 203 - 210
  • [35] Successful eradication of acquired factor-VIII-inhibitor using single low-dose rituximab
    Wermke, Martin
    von Bonin, Malte
    Cehrisch, Siegmund
    Siegert, Gabriele
    Ehninger, Gerhard
    Platzbecker, Uwe
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 (03): : 521 - 522
  • [36] Lower inhibitor risk of plasma-derived factor VIII concentrates versus recombinant factor VIII concentrates in patients with severe haemophilia A : result from SIPPET study and comments
    Biron-Andreani, Christine
    Diaz, Isabelle
    Navarro, Robert
    Schved, Jean-Francois
    HEMATOLOGIE, 2019, 25 (02): : 93 - 99
  • [37] Successful immune tolerance treatment with monoclonal or recombinant factor VIII concentrates in high responding inhibitor patients
    Rocino, A
    de Biasi, R
    VOX SANGUINIS, 1999, 77 : 65 - 69
  • [38] Immune tolerance induction (ITI) according to the Bonn protocol in haemophilia A patients with inhibitors using a plasma-derived VWF-containing factor VIII concentrate: two paediatric case reports
    Lohse, J.
    Gehrisch, S.
    Escuriola-Ettingshausen, C.
    Kreuz, W.
    Knoefler, R.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2013, 11 : 1073 - 1074
  • [39] The role of VWF in FVIII/VWF concentrates: biochemical characterization of three different plasma-derived factor VIII products
    Cristofaro, Raimondode
    Lancellotti, Stefano
    Filippis, Vincenzode
    Acquasaliente, Laura
    Valsecchi, Carla
    Garagiola, Sabella
    Peyvandi, Flora
    HAEMOPHILIA, 2014, 20 : 26 - 26
  • [40] Low incidence of FVIII inhibitors in patients treated with plasma derived FVIII concentrates and the outcomes of immune tolerance induction with FVIII/vWF concentrates
    Batorova, Angelika
    Bubanska, Eva
    Morongova, Anna
    Jankovicova, Denisa
    Prigancova, Tatiana
    HAEMOPHILIA, 2014, 20 : 47 - 48
12345